# Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum

> **NCT03386578** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 780 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
- **BEHAVIORAL:** Behavioral HIV risk reduction package
- **BEHAVIORAL:** Enhanced adherence support

## Key facts

- **NCT ID:** NCT03386578
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-03
- **Primary completion:** 2023-10-25
- **Final completion:** 2024-02-24
- **Target enrollment:** 780 (ACTUAL)
- **Last updated:** 2025-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386578, "Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03386578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*